Navigation Links
Biochemical signature predicts progression to Alzheimer's disease
Date:12/14/2011

A study led by Research Professor Matej Oreič from VTT Technical Research Centre of Finland suggests that Alzheimer's disease is preceded by a molecular signature indicative of hypoxia and up-regulated pentose phosphate pathway. This indicator can be analysed as a simple biochemical assay from a serum sample months or even years before the first symptoms of the disease occur. In a healthcare setting, the application of such an assay could therefore complement the neurocognitive assessment by the medical doctor and could be applied to identify the at-risk patients in need of further comprehensive follow-up.

Alzheimer's disease (AD) is a growing challenge to the health care systems and economies of developed countries with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing ageing of populations.

The progression of Alzheimer's disease (AD) is gradual, with the subclinical stage of illness believed to span several decades. The pre-dementia stage, also termed mild cognitive impairment (MCI), is characterised by subtle symptoms that may affect complex daily activities. MCI is considered as a transition phase between normal aging and AD. MCI confers an increased risk of developing AD, although the state is heterogeneous with several possible outcomes, including even improvement back to normal cognition.

What are the molecular changes and processes which define those MCI patients who are at high risk of developing AD? The teams led by Matej Oreič from VTT and Hilkka Soininen from the University of Eastern Finland set out to address this question, and the results were published on 13th Dec. 2011 in Translational Psychiatry.

The team used metabolomics, a high-throughput method for detecting small metabolites, to produce profiles of the serum metabolites associated with progression to AD. Serum samples were collected at baseline when the patients
'/>"/>

Contact: Matej Oresic
matej.oresic@vtt.fi
358-207-224-491
VTT Technical Research Centre of Finland
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. News tips from the May/June issue of Physiological and Biochemical Zoology
4. Biochemical and Molecular Engineering XVII Conference
5. NutriLuxe Offers Personal, At-Home Body Biochemical Balance Test
6. Toronto researchers obtain detailed molecular signature for Tankyrase
7. Lung cancer signatures in blood samples may aid in early detection
8. Penn researchers find neural signature of mental time travel
9. Researchers home in on genetic signature of esophageal cancer
10. Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
11. Molecular signatures may aid fight against pediatric liver disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Each year, the Susan G. Komen ... and awareness for breast cancer. This year, Dr. Mark Deutsch ... as the entertainment sponsor for the 25th annual Susan G. ... at the Lenox Square Mall. , The Komen organization hopes ... raise $1.2 million. Perimeter Plastic Surgery has not only taken ...
(Date:5/4/2015)... May 04, 2015 TROY Healthcare Solutions ... North Atlantic Regional User Group (RUG) Conference in Baltimore, ... North Atlantic Regional User Group provides an opportunity for ... explore the exhibitor gallery. , In addition to sponsoring ... the Cerner North Atlantic RUG Conference. Attendees can stop ...
(Date:5/4/2015)... In May of 2010, after two years of ... the wake of this tragedy, Ty’s parents Kirk and Laura ... the grim reality of bullying and its devastating consequences. Stand ... Laura to share their story and offer education and tools ... family — a mission that took the Smalley family all ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... day in health-related lost productivity equals 56 cents per share ... 8 /PRNewswire/ -- In today,s challenging economy every ... for business success. To help companies make the business case ... a DVD about the experience of a Fortune 500 company ...
... Blue Cross and Blue Shield of Georgia,(BCBSGa) today announced ... more than 996 not-for-profit organizations in 2009 as part,of the ... of Georgia Foundation will match 50 percent of associate pledges,increasing ... "Every day our associates work to ...
... The end of fall marks an exciting time,for ... their,professional careers. Fellows from around the world will gather ... Interventions (SCAI),Third Annual Interventional Cardiology Fall Fellows Course in ... Given the aging population and the increasing number ...
... low risk of developing intractable disease , , MONDAY, Dec. ... giving anti-seizure medication to children with epilepsy who,ve achieved ... at high risk of later developing intractable epilepsy, a ... affects about 10 percent of children with epilepsy, is ...
... drug treatment, researchers note , , MONDAY, Dec. 8 (HealthDay ... genes of more than 40,000 people has identified 11 ... as LDL cholesterol and triglycerides. , "These locations point ... cholesterol in humans," said Dr. Sekar Kathiresan, director of ...
... Inc.,(Nasdaq: ARNA ) announced today that ... Monday, December 15, 2008, beginning at approximately 12:00 ... Jack Lief,President and Chief Executive Officer, Dominic P. ... and William R. Shanahan, M.D., Vice,President and Chief ...
Cached Medicine News:Health News:Integrated Benefits Institute Helps Employers Make the Business Case for Health and Productivity Improvement 2Health News:Blue Cross and Blue Shield of Georgia Associates Pledge More Than $1.3 Million to Community Organizations 2Health News:Blue Cross and Blue Shield of Georgia Associates Pledge More Than $1.3 Million to Community Organizations 3Health News:SCAI's Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field 2Health News:SCAI's Annual Fall Fellows Course Prepares New Interventional Cardiologists to Work in the Field 3Health News:Seizure Meds Can Be Safely Withdrawn From Kids With Epilepsy 2Health News:11 New Cholesterol Genes Identified 2Health News:11 New Cholesterol Genes Identified 3Health News:Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008 2Health News:Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008 3
(Date:5/4/2015)... May 4, 2015 Southfield Capital, ... firm, announced today that it completed a ... Communications. BioPharm specializes in the development and multi-channel ... pharmaceutical and biotechnology industries. Through ... shareholders half of their invested capital and ...
(Date:5/4/2015)... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Conference on Monday, May 18, 2015, in New York City.  ... Officer will be making a presentation on PAREXEL and discussing ... webcast of the presentation will be available through the "Investors" ... Upcoming Events portion of the main page, and a replay ...
(Date:5/4/2015)... Calif. , May 4, 2015  Impax Laboratories, ... filled two key executive leadership roles, appointing  Donna M. ... Deborah M. Penza , as Senior Vice President, Chief ... report to Impax,s President and Chief Executive Officer, ... Donna and Deborah have joined the Impax team," said ...
Breaking Medicine Technology:Southfield Capital and BioPharm Communications Announce Dividend Recapitalization 2PAREXEL International to Present at UBS Healthcare Conference 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3
... March 31, 2011 Virtual Radiologic (vRad), ... 2011 Stevie® Award for Sales & Customer Service. vRad® ... managed via the Internet, that provides secure access to ... team via mobile digital devices and the Internet. vRad ...
... WALTHAM, Mass., March 31, 2011 Syndax Pharmaceuticals, Inc., ... on entinostat, an oral, highly selective, class I histone ... Annual American Association for Cancer Research meeting April 2 ... "The breadth of exciting data being presented at AACR ...
Cached Medicine Technology:Virtual Radiologic Wins Stevie® Award for Improving Patient Care through Mobile Technology 2Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting 2Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting 3Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting 4